Get the Stockscreener App
2.84
1.05%
-0.03
After Hours:
2.83
-0.010
-0.35%
Affimed N V stock is traded at $2.84, with a volume of 155.89K.
It is down -1.05% in the last 24 hours and down -14.59% over the past month.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
See More
Previous Close:
$2.87
Open:
$2.87
24h Volume:
155.89K
Relative Volume:
1.48
Market Cap:
$45.57M
Revenue:
$19.91M
Net Income/Loss:
$-127.11M
P/E Ratio:
-3.6438
EPS:
-0.7794
Net Cash Flow:
$-132.44M
1W Performance:
+4.41%
1M Performance:
-14.59%
6M Performance:
-32.22%
1Y Performance:
-36.89%
1-Day Range:
$2.71
$2.92
1-Week Range:
$2.61
$3.0982
52-Week Range:
$2.61
$8.95
Affimed N V Stock (AFMD) Company Profile
Compare AFMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AFMD
Affimed N V
|
2.84 | 45.57M | 19.91M | -127.11M | -132.44M | -0.7794 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Affimed N V Stock (AFMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-22 | Initiated | H.C. Wainwright | Buy |
| Oct-10-22 | Downgrade | Stifel | Buy → Hold |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-23-22 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-21 | Initiated | Truist | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Aug-12-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| May-19-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Dec-10-15 | Initiated | Laidlaw | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Sep-09-15 | Initiated | Jefferies | Hold |
| Aug-06-15 | Reiterated | Oppenheimer | Outperform |
| Jun-22-15 | Reiterated | Jefferies | Buy |
View All
Affimed N V Stock (AFMD) Latest News
Affimed Q3 2024 Earnings Preview - MSN
Is Affimed N.V. (AFMD) the Best German Stock to Buy Now? - Insider Monkey
10 Best German Stocks To Buy Now - Insider Monkey
Affimed's (AFMD) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00 - MarketBeat
Affimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call Transcript - Insider Monkey
Affimed's (AFMD) Buy Rating Reiterated at HC Wainwright - MarketBeat
Earnings call: Affimed reports promising results and strategic focus - Investing.com India
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating F - GuruFocus.com
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo Finance
Affimed Reports Q3 2024 Financial Results and Updates - TipRanks
Affimed N.V.: Q3 Earnings Snapshot - Houston Chronicle
Affimed NV earnings missed by €0.09, revenue fell short of estimates - Investing.com Canada
Affimed Faces Growing Losses Amid Financial Struggles - TipRanks
Affimed Reports Third Quarter 2024 Financial Results & Business Update - The Manila Times
Affimed Q3 Revenue Drops 90%, but Net Loss Narrows as R&D Costs Decline | AFMD Stock News - StockTitan
Affimed (AFMD) Scheduled to Post Quarterly Earnings on Thursday - Defense World
Affimed to Report Third Quarter 2024 Financial Results and Corporate Update on November 14, 2024 - Marketscreener.com
Affimed (AFMD) Scheduled to Post Earnings on Thursday - MarketBeat
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024 - GlobeNewswire
Affimed (AFMD) Sets Q3 2024 Earnings Call for Nov 14: Immuno-Oncology Updates Ahead | AFMD Stock News - StockTitan
Affimed (NASDAQ:AFMD) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Affimed Announces Acceptance of Three Abstracts at the 2024 - GlobeNewswire
Affimed to Present Promising AML Treatment Data at ASH 2024 Annual Meeting | AFMD Stock News - StockTitan
Affimed (NASDAQ:AFMD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Affimed (NASDAQ:AFMD) Given Average Rating of “Buy” by Analysts - Defense World
Affimed (NASDAQ:AFMD) Short Interest Update - MarketBeat
683 Capital Management, LLC Expands Stake in Affimed NV - Yahoo Finance
Affimed Appoints New Director Amid Strategic Moves - TipRanks
Affimed N : Annual General Meeting Results Form 6 K - Marketscreener.com
Affimed N : Presentation - Marketscreener.com
Analysts Set Affimed (NASDAQ:AFMD) Target Price at $20.00 - MarketBeat
Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN
Affimed appoints Shawn Leland as chief executive officer - MSN
Affimed (NASDAQ:AFMD) Sees Significant Decrease in Short Interest - MarketBeat
AFMDAffimed N.V. Latest Stock News & Market Updates - StockTitan
Affimed N.V. Announces Upcoming EGM - TipRanks
Affimed to Present at the Cantor Global Healthcare Conference 2024 - GlobeNewswire
Affimed (NASDAQ:AFMD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Cantor Fitzgerald Reiterates "Overweight" Rating for Affimed (NASDAQ:AFMD) - MarketBeat
Affimed (NASDAQ:AFMD) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Affimed N.V. (NASDAQ:AFMD) Q2 2024 Earnings Call Transcript - Insider Monkey
HC Wainwright Reaffirms Buy Rating for Affimed (NASDAQ:AFMD) - MarketBeat
Earnings call: Affimed reports promising clinical results and stable finances By Investing.com - Investing.com Australia
Affimed N V Stock (AFMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):